Detalhe da pesquisa
1.
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
BMC Cancer
; 24(1): 16, 2024 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38166764
2.
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Eur J Clin Pharmacol
; 79(2): 243-248, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36520173
3.
Is pancreatic giant cell tumor resistant to standard chemotherapy?
Anticancer Drugs
; 33(8): 758-760, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35946539
4.
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study.
Eur J Clin Pharmacol
; 78(12): 1973-1979, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36266366
5.
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
BMC Cancer
; 24(1): 114, 2024 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38262962
6.
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Expert Opin Pharmacother
; 25(4): 477-484, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38568074
7.
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
J Cancer Res Clin Oncol
; 149(11): 9183-9189, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37184681
8.
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Bosn J Basic Med Sci
; 22(5): 818-825, 2022 Sep 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35460397